Combination immunotherapy for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have metastatic or recurrent melanoma that has not responded to standard first-line treatment or cannot be surgically removed.
- Your tumor must test positive for specific melanoma markers.
- You need to be generally well enough to carry out daily activities (Karnofsky score of 70% or higher).
- Your liver, kidney, heart, and blood counts must be within acceptable ranges.
- You cannot have untreated brain metastases, active infections like HIV or hepatitis, or have had CAR T-cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes). The cells are taken from a tumor sample, multiplied in a lab, and given back to you to help fight the cancer. It's for people with melanoma that has not responded to standard immunotherapy.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
This trial tests a combination of three drugs (interferon, an immunotherapy drug called toripalimab, and an anti-cancer drug called anlotinib) in people with advanced melanoma that cannot be removed with surgery. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a type of immune cell therapy called cytokine-induced killer cells for people with advanced melanoma that has not responded to other treatments. It aims to see if these cells can help shrink or slow down the cancer.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.